Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Generating a Novel Transgenic Model and Developing Gene-Editing Therapeutic Approaches for Retinitis Pigmentosa

FY 2019-20

Summary
"Retinitis Pigmentosa (RP) is a vision-threatening disorder that is characterized by progressive blindness due to retinal degeneration (RD). According to Fighting Blindness Canada, 1 in 3500 Canadians are affected by this inherited retinal disease. Thousands of mutations in over a hundred genes cause RP, making it impossible to develop a standard routine treatment for diagnosed patients. However, recent advancements in gene therapy provide the opportunity to develop patient-based therapeutics for specific underlying mutations. Rhodopsin is a key photosensitive pigment of rod cells encoded by the RHO gene and mutation-induced misfolding of this protein has been identified to underly RP. In this project, we aim to use the cutting-edge CRISPR/Cas9-mediated gene editing strategy in X. laevis models for RP to prevent RD-associated RHO mutations. In the conventional gene-editing approach carried out by our group, a single edit resulted in desirable curative outcomes in 2/3 of cases, while in the remaining third it led to exacerbation of the RD phenotype or had no effect. By inducing two simultaneous edits and cutting out the start codon for the RHO gene, we aim to completely eliminate the expression of misfolded rhodopsin protein. In order to efficiently and reliably transfer our findings from lab benches into the clinics, we also aim to develop a humanized mouse model that expresses the mutated human rhodopsin gene in a mammalian environment. This novel model will facilitate a better understanding of RP disease mechanisms, while providing an ideal setting to develop gene-editing therapeutics. Given that the mutated human rhodopsin gene will be targeted for treatment development in this mouse, successful approaches can be more directly translated into clinical trials."
Program
Master's Award: Canada Graduate Scholarships
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
428839
Name
Ghaseminejad Tafres Amirfarhad
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Generating a Novel Transgenic Model and Developing Gene-Editing Therapeutic Approaches for Retinitis Pigmentosa
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Crispr-Cas9; Crispr-Humanized Minimally Mouse Model; Gene-Editting; Light-Exacerbated Retinal Degeneration; Retinal Degeneration; Retinitis Pigmentosa; Rhodopsin; Rod Photoreceptors; T4k Rho Mutation; Xenopus Laevis
Abstract
"Retinitis Pigmentosa (RP) is a vision-threatening disorder that is characterized by progressive blindness due to retinal degeneration (RD). According to Fighting Blindness Canada, 1 in 3500 Canadians are affected by this inherited retinal disease. Thousands of mutations in over a hundred genes cause RP, making it impossible to develop a standard routine treatment for diagnosed patients. However, recent advancements in gene therapy provide the opportunity to develop patient-based therapeutics for specific underlying mutations. Rhodopsin is a key photosensitive pigment of rod cells encoded by the RHO gene and mutation-induced misfolding of this protein has been identified to underly RP. In this project, we aim to use the cutting-edge CRISPR/Cas9-mediated gene editing strategy in X. laevis models for RP to prevent RD-associated RHO mutations. In the conventional gene-editing approach carried out by our group, a single edit resulted in desirable curative outcomes in 2/3 of cases, while in the remaining third it led to exacerbation of the RD phenotype or had no effect. By inducing two simultaneous edits and cutting out the start codon for the RHO gene, we aim to completely eliminate the expression of misfolded rhodopsin protein. In order to efficiently and reliably transfer our findings from lab benches into the clinics, we also aim to develop a humanized mouse model that expresses the mutated human rhodopsin gene in a mammalian environment. This novel model will facilitate a better understanding of RP disease mechanisms, while providing an ideal setting to develop gene-editing therapeutics. Given that the mutated human rhodopsin gene will be targeted for treatment development in this mouse, successful approaches can be more directly translated into clinical trials."
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ghaseminejad Tafres, Amirfarhad
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~